These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 17371231)

  • 41. Fine tuning the immune response with PI3K.
    Fruman DA; Bismuth G
    Immunol Rev; 2009 Mar; 228(1):253-72. PubMed ID: 19290933
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phosphoinositide 3-kinase regulates the phosphorylation of NADPH oxidase component p47(phox) by controlling cPKC/PKCdelta but not Akt.
    Yamamori T; Inanami O; Nagahata H; Kuwabara M
    Biochem Biophys Res Commun; 2004 Apr; 316(3):720-30. PubMed ID: 15033459
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Introduction: multifaceted roles of lipids and their catabolites in immune cell signaling.
    Ott VL; Cambier JC
    Semin Immunol; 2002 Feb; 14(1):1-6. PubMed ID: 11884225
    [No Abstract]   [Full Text] [Related]  

  • 44. Inhibition of phosphoinositide 3-kinase enhances TRIF-dependent NF-kappa B activation and IFN-beta synthesis downstream of Toll-like receptor 3 and 4.
    Aksoy E; Vanden Berghe W; Detienne S; Amraoui Z; Fitzgerald KA; Haegeman G; Goldman M; Willems F
    Eur J Immunol; 2005 Jul; 35(7):2200-9. PubMed ID: 15940673
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Importance of phosphoinositide 3-kinase gamma in the host defense against pneumococcal infection.
    Maus UA; Backi M; Winter C; Srivastava M; Schwarz MK; Rückle T; Paton JC; Briles D; Mack M; Welte T; Maus R; Bohle RM; Seeger W; Rommel C; Hirsch E; Lohmeyer J; Preissner KT
    Am J Respir Crit Care Med; 2007 May; 175(9):958-66. PubMed ID: 17322108
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phosphatidylinositol 3-kinase isoforms as novel drug targets.
    Błajecka K; Borgström A; Arcaro A
    Curr Drug Targets; 2011 Jun; 12(7):1056-81. PubMed ID: 21291386
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents.
    Ward SG; Finan P
    Curr Opin Pharmacol; 2003 Aug; 3(4):426-34. PubMed ID: 12901953
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Towards an understanding of isoform specificity in phosphoinositide 3-kinase signalling in lymphocytes.
    Fruman DA
    Biochem Soc Trans; 2004 Apr; 32(Pt 2):315-9. PubMed ID: 15046598
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The PI3K p110delta controls T-cell development, differentiation and regulation.
    Patton DT; Garçon F; Okkenhaug K
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):167-71. PubMed ID: 17371229
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond.
    Medina-Tato DA; Ward SG; Watson ML
    Immunology; 2007 Aug; 121(4):448-61. PubMed ID: 17614878
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of class IA phosphoinositide 3-kinase in B lymphocyte development and functions.
    Koyasu S
    Biochem Soc Trans; 2004 Apr; 32(Pt 2):320-5. PubMed ID: 15046599
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structural insight into substrate specificity and regulatory mechanisms of phosphoinositide 3-kinases.
    Djordjevic S; Driscoll PC
    Trends Biochem Sci; 2002 Aug; 27(8):426-32. PubMed ID: 12151228
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances.
    So L; Fruman DA
    Biochem J; 2012 Mar; 442(3):465-81. PubMed ID: 22364281
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Control of CD4
    Cameron B; Zaheer SA; Dominguez-Villar M
    Curr Top Microbiol Immunol; 2022; 436():197-216. PubMed ID: 36243845
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Signalling by PI3K isoforms: insights from gene-targeted mice.
    Vanhaesebroeck B; Ali K; Bilancio A; Geering B; Foukas LC
    Trends Biochem Sci; 2005 Apr; 30(4):194-204. PubMed ID: 15817396
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Role of p110δ in the Development and Activation of B Lymphocytes.
    Newman R; Turner M
    Adv Exp Med Biol; 2015; 850():119-35. PubMed ID: 26324350
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phosphoinositide 3-kinase δ (PI3Kδ) in respiratory disease.
    Stokes CA; Condliffe AM
    Biochem Soc Trans; 2018 Apr; 46(2):361-369. PubMed ID: 29523773
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lymphocyte cell motility: the twisting, turning tale of phosphoinositide 3-kinase.
    Oak JS; Matheu MP; Parker I; Cahalan MD; Fruman DA
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1109-13. PubMed ID: 17956290
    [TBL] [Abstract][Full Text] [Related]  

  • 59. T and B-cell signaling in activated PI3K delta syndrome: From immunodeficiency to autoimmunity.
    Preite S; Gomez-Rodriguez J; Cannons JL; Schwartzberg PL
    Immunol Rev; 2019 Sep; 291(1):154-173. PubMed ID: 31402502
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of PI3K signalling in the B cell response to antigen.
    Hodson DJ; Turner M
    Adv Exp Med Biol; 2009; 633():43-53. PubMed ID: 19209680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.